Phase I metabolism and disposition study of radiolabelled XP 23829 in healthy subjects

Trial Profile

Phase I metabolism and disposition study of radiolabelled XP 23829 in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2013

At a glance

  • Drugs XP 23829 (Primary)
  • Indications Multiple sclerosis; Psoriasis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Sep 2013 Status changed from recruiting to completed.
    • 09 Sep 2013 Results were reported in a a XenoPort media release.
    • 06 Aug 2013 Results are expected later in the third quarter of 2013, according to a XenoPort media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top